Nicola Wilsher is the Vice President of DMPK and Preclinical Development and joined Astex in 2010. Nicola has more than 20 years of experience in the pharmaceutical industry. Early in her career at Rhone-Poulenc Rorer, UK, Nicola introduced higher throughput technologies to address the need for understanding DMPK properties earlier in the drug discovery process. Nicola has worked on numerous discovery and preclinical development projects in the anti-inflammatory, anti-infectives and oncology therapeutic areas. In 2004 Nicola joined the Institute of Cancer Research, UK to focus on the discovery of novel anticancer agents and contributed to the development of Abiraterone. Nicola studied Biopharmacy at King’s College London and gained her PhD at Leicester School of Pharmacy.